DrugPatentWatch Database Preview

Details for Patent: 5,852,195

Which drugs does patent 5,852,195 protect, and when does it expire?

Patent 5,852,195 protects APTIVUS and is included in two NDAs.

Protection for APTIVUS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty patent family members in thirty-one countries.

Summary for Patent: 5,852,195

Title:	Pyranone compounds useful to treat retroviral infections
Abstract:	The present invention relates to compounds of formulae (I) and (II) which are pyran-2-ones, 5,6-dihydro-pyran-2-ones, 4-hydroxy-benzopyran-2-ones, 4-hydroxy-cycloalkyl[b]pyran-2-ones, and derivatives thereof, useful for inhibiting a retrovirus in a mammalian cell infected with said retrovirus, wherein R.sub.10 and R.sub.20 taken together are formulae (III) and (IV). ##STR1##
Inventor(s):	Romines; Karen Rene (Paw Paw, MI), Bundy; Gordon L. (Portage, MI), Schwartz; Theresa M. (Kalamazoo, MI), Tommasi; Ruben A. (Whitehouse Station, NJ), Strohbach; Joseph W. (Mendon, MI), Turner; Steven Ronald (Kalamazoo, MI), Thaisrivongs; Suvit (Kalamazoo, MI), Aristoff; Paul Adrian (Kalamazoo, MI), Johnson; Paul D. (Portage, MI), Skulnick; Harvey Irving (Kalamazoo, MI), Skaletzky; Louis L. (Kalamazoo, MI), Anderson; David John (Kalamazoo, MI), Morris; Joel (Kalamazoo, MI), Gammill; Ronald B. (Portage, MI), Luke; George P. (Lexington, MA)
Assignee:	Pharmacia & Upjohn Company (Kalamazoo, MI)
Application Number:	08/809,224
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 5,852,195

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Boehringer Ingelheim	APTIVUS	tipranavir	CAPSULE;ORAL	021814-001	Jun 22, 2005		RX	Yes	Yes	➤ Sign Up	➤ Sign Up			Y		➤ Sign Up
Boehringer Ingelheim	APTIVUS	tipranavir	SOLUTION;ORAL	022292-001	Jun 23, 2008		RX	Yes	Yes	➤ Sign Up	➤ Sign Up			Y		➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Foreign Priority and PCT Information for Patent: 5,852,195

PCT Information
PCT Filed	May 04, 1995	PCT Application Number:	PCT/US95/05219
PCT Publication Date:	November 16, 1995	PCT Publication Number:	WO95/30670

Non-Orange Book US Patents Family Members for Patent 5,852,195

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
6,169,181	Compounds useful to treat retroviral infections	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 5,852,195

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
China	1329378	➤ Sign Up
China	1539825	➤ Sign Up
China	1749252	➤ Sign Up
Colombia	4810313	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 5,852,195

Foreign Priority and PCT Information for Patent: 5,852,195

For more information try a trial or see the plans and pricing